Add this topic to your myFT Digest for news straight to your inbox
National security concerns in Washington threaten company that derives majority of its revenues from the US
One-year-old healthcare start-up gains investment from venture groups including General Catalyst and Andreessen Horowitz
Officials warn weaknesses in surveillance will hinder vaccine development as countries struggle to agree accord
Eli Lilly and Novo Nordisk’s weight-loss drugs have transformed their fortunes but a backlash could be looming
Worldwide study finds neurological conditions affect billions as life expectancy rises
Groups including Legal & General among those pushing for stricter health targets at world’s biggest food company
Retail group agrees first partnership with a big drug company since launching online pharmacy business in 2020
Booming sector raises tough questions for ESG investors
Industry regulator has shut 804 for-profit facilities since 2011, study shows
We risk forgetting the lessons of the Covid pandemic
Divisions between richer and poorer nations threaten progress on talks as Lancet study shows scale of Covid toll
French government bill to propose giving some terminally ill the option to request ‘aid in dying’
A number of other countries have now legalised the practice
Breakthrough medicine will now be subject to further review by committee of independent experts
Drugmaker releases promising trial results for a pill and expects to enter China this year
Chief executive of aspirin-to-Roundup group has limited options to sort fallout of ill-fated Monsanto purchase
With the pandemic boom over, consumer medical start-ups now face fickle customers and a crowded market place
Avid Bioservices had an oopsie
There is still room for growth in Japan’s $53bn dispensing pharmacy market
The company’s deleveraging route looks long and distinctly uncertain
Bill Anderson quashes speculation after suspending break-up of indebted German drugs-to-pesticides group
Bill Anderson expects further profit declines at the aspirin-to-agriculture conglomerate in 2024
Nice fails to approve Enhertu due to value-for-money concerns despite it being recommended in Scotland
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
Cultivation of stem cells extracted from amniotic fluid will help treat congenital conditions
International Edition